0000876661-17-000588.txt : 20171003
0000876661-17-000588.hdr.sgml : 20171003
20171003130115
ACCESSION NUMBER: 0000876661-17-000588
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20171003
DATE AS OF CHANGE: 20171003
EFFECTIVENESS DATE: 20171003
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ALERE INC.
CENTRAL INDEX KEY: 0001145460
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 043565120
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16789
FILM NUMBER: 171116994
BUSINESS ADDRESS:
STREET 1: 51 SAWYER ROAD
STREET 2: SUITE 200
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7816473900
MAIL ADDRESS:
STREET 1: 51 SAWYER ROAD
STREET 2: SUITE 200
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: INVERNESS MEDICAL INNOVATIONS INC
DATE OF NAME CHANGE: 20010720
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NEW YORK STOCK EXCHANGE LLC
CENTRAL INDEX KEY: 0000876661
IRS NUMBER: 000000000
STATE OF INCORPORATION: NY
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-2060
MAIL ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NEW YORK STOCK EXCHANGE INC
DATE OF NAME CHANGE: 19910628
25-NSE
1
primary_doc.xml
X0203
0000876661
NEW YORK STOCK EXCHANGE LLC
1145460
ALERE INC.
001-16789
51 Sawyer Road, Suite 200
Waltham
MA
MASSACHUSETTS
02453
(781) 647-3900
Common Stock
17 CFR 240.12d2-2(a)(3)
Benjamin Sawyer
Manager
2017-10-03
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 16, 2017, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on October 3, 2017 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
The merger between Alere Inc. and Angel Sub, Inc., a wholly owned subsidiary of Abbott Laboratories became effective before market open on October 3, 2017. Each share of common stock of Alere Inc. was converted into $51.00 in cash.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on October 3, 2017.